Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

655 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness of screening for proteinuria.
Gansevoort RT, de Jong PE, Postma MJ. Gansevoort RT, et al. Among authors: postma mj. JAMA. 2004 Mar 24;291(12):1442-3; author reply 1443. doi: 10.1001/jama.291.12.1442. JAMA. 2004. PMID: 15039405 No abstract available.
Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ; PREVEND IT Study Group. Atthobari J, et al. Among authors: postma mj. Clin Ther. 2006 Mar;28(3):432-44. doi: 10.1016/j.clinthera.2006.03.012. Clin Ther. 2006. PMID: 16750458
Towards a healthier discount procedure.
Klock RM, Brouwer WB, Annemans LJ, Bos JM, Postma MJ. Klock RM, et al. Among authors: postma mj. Expert Rev Pharmacoecon Outcomes Res. 2005 Feb;5(1):59-63. doi: 10.1586/14737167.5.1.59. Expert Rev Pharmacoecon Outcomes Res. 2005. PMID: 19807560
Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C, Gansevoort RT, Pechlivanoglou P, Visser ST, van Toly FF, de Jong-van den Berg LT, de Jong PE, Postma MJ; Prevention of Renal and Vascular End Stage Disease Study Group. Boersma C, et al. Among authors: postma mj. Clin Ther. 2010 Jun;32(6):1103-21. doi: 10.1016/j.clinthera.2010.06.013. Clin Ther. 2010. PMID: 20637965 Free article.
655 results